Lilia Pedrosa has a degree in Pharmaceutical Sciences (2000-2005) from the Faculty of Pharmacy at University of Coimbra. During her 6-year PharmD degree studies she experienced 1-year abroad at University of Barcelona (Spain) and a summer internship at the Hospital in Czech Republic, as a pharmacist.
Lilia started her path in Research in 2008 as a Researcher in the project “The increase in the bioavailability of oral insulin through the nanoencapsulation into polysaccharides” at University of Coimbra.
In 2007, Lilia followed a Post Graduation in “Pharmacy and the Medicine Law”, Biomedical Law Centre of the Faculty of Law of the University of Coimbra starting in parallel to her first job as PharmD – Regularity Affairs Officer.
By the dynamic and ambitious personality, Lilia started her PhD in 2009 at Erasmus Medical Center-Rotterdam and Netherlands Cancer Institute-Amsterdam, The Netherlands), where she worked in close collaboration with a biotech company CERONCO. In 2014, Lilia concluded her PhD in Nanomedicine/Oncology, finalizing her project with a thesis entitled of “Liposomal Nanomedicine with Short Chain Sphingolipids Modulate Tumor Cell Membrane Permeability and Improve Chemotherapy”.
Following 9-yerars of international experience, Lilia worked within Pharma for 3-years. In 2014-2015 at BBB Therapeutics (The Netherlands) as a Scientist Target CNS and in 2016-2018 at ProQR Therapeutics (The Netherlands), focusing on development of drugs to treat severe genetic disorders, as a Scientist Pharmaceutics.
Back home, in Portugal since 2018, Lilia performed as a Post-Doc at Champalimaud Foundation within Immunology and lately at Faculty of Pharmacy in University of Lisbon (2019-2021), at Toxicology department in the field of CNS diseases developing nanotherapeutic formulations to treat Glioblastoma.